抗体フラグメント市場：タイプ別、抗体タイプ別、用途別 - 2024年～2030年の世界予測

抗体フラグメント市場規模は2023年に77億2,000万米ドルと推計され、2024年には80億7,000万米ドルに達し、CAGR 4.36％で2030年には104億2,000万米ドルに達すると予測されています。

抗体フラグメントとは、免疫反応を引き起こす体内の異物である特定の種類の抗原に結合することができる抗体の一部を指します。抗体フラグメントは通常、抗体全体から派生したもので、酵素消化や遺伝子工学技術によって開発されます。この市場開拓の主な要因は、自己免疫疾患などの慢性疾患を治療するための標的療法の採用が増加していることです。また、遺伝子技術や生化学技術の進歩も、これらのフラグメントの生産と工学的処理を強化する道を開き、成長を後押ししています。研究開発資金の絶え間ない増加と、特に先進国における強固なヘルスケア・インフラが、市場全体の成長に寄与しました。しかし、抗体フラグメントの生産と精製には高いコストがかかるため、市場の成長は制限される可能性があります。また、新興市場における規制上の課題や認識不足も、潜在的な成長制約要因となっています。新たな可能性としては、抗体フラグメントを使用した革新的な医薬品の開発や、未開拓の疾患領域での使用が挙げられます。さらに、新興市場における製薬およびバイオテクノロジーの取り組みの拡大と統合も、抗体フラグメント市場の成長にとって大きな機会となります。

タイプシングルドメイン抗体（sdAbs）は、その安定性と柔軟な結合性により、用途の面で利用が急増しています。

F（ab）フラグメントは、抗原結合部位（Fab）を1つ持つ小さな抗体フラグメントです。保存されたFc領域を持たないため、抗体依存性細胞傷害性によって細胞を破壊することはできないです。画像診断や診断薬などに応用されます。F（ab'）2フラグメントは、F（ab）と比較して抗原結合部位が2つあり、抗体が標的により強力に結合することを可能にします。F（ab'）2フラグメントは、F（ab）2フラグメントと比較して抗原結合部位が2つあり、より強力にターゲットに結合することができます。シングルドメイン抗体（sdAbs）は、高い溶解性、熱安定性、酵素活性部位への結合能で知られ、治療薬や研究においてその用途は多岐にわたる。一本鎖可変フラグメント（scFv）はモノクローナル抗体と同様の結合特異性を持っています。抗体誘導体の設計のための効率的なツールとして、標的ドラッグデリバリーや免疫療法に好まれています。

抗体タイプ：モノクローナル抗体の標的治療における高い特異性により、モノクローナル抗体の利用が増加しています。

モノクローナル抗体（MAbs）は、単一のB細胞クローンによって作られる同一の抗体です。モノクローナル抗体は、単一の抗原決定基に対して特異的であるため、高い特異性、安定した品質、無制限の供給が可能です。例えば、特定のタンパク質の検出や定量、腫瘍や自己免疫疾患などの治療分野、目的の抗原のみを検出することが重要な細胞や組織の染色などです。ポリクローナル抗体（PAbs）は、体内の異なるB細胞クローンによって産生される抗体の混合物であり、それぞれが抗原の異なるエピトープを認識します。その結果、特定の条件下では有益な幅広い応答が得られます。ポリクローナル抗体は、ウェスタンブロット、ELISA、免疫組織化学などの検出系で強固なシグナルを必要とする研究に好まれます。様々な条件下で複数のエピトープに結合できるため、PAbsは抗原のコンフォメーションのわずかな変化にも寛容です。モノクローナル抗体よりも高い全体的な結合親和性を提供することができます。

アプリケーションがん治療における抗体フラグメントの応用の進化

がん治療における抗体フラグメントは、がん研究のブレークスルーとみなされています。その小さなサイズは、全抗体よりも効率的にがん細胞に浸透し結合します。さらに、健康な細胞への付随的なダメージのリスクを最小限に抑え、より的を絞った治療アプローチを提供します。抗体フラグメントは免疫不全の治療において極めて重要です。抗体フラグメントは、不足している、あるいは不十分な抗体反応を補い、患者の感染症を撃退する能力を向上させる。また、特定の疾患バイオマーカーを標的とするよう設計できるため、より個別化された治療が可能となります。がん治療では主にがん細胞の標的除去に重点が置かれるが、免疫不全症では身体の免疫反応を高めるために抗体フラグメントが使用されます。

地域別の洞察

南北アメリカは、市場成長の道を開く継続的な研究イニシアチブにより、抗体フラグメント市場において重要な地位を占めています。これらの国々における購買行動は、個別化医療の出現によって大きく左右され、疾患特異的なアプリケーションに顕著な焦点が当てられています。次世代ヘルスケア技術への民間および政府機関の投資が増加しており、さらなる成長が見込まれています。欧州、中東・アフリカ（EMEA）は、健康意識の高まりと公衆衛生のための政府の取り組みによって、抗体フラグメントの急成長市場を示しています。これらの地域では生活習慣病が増加しており、ヘルスケア分野で革新的な治療薬が必要とされています。EU諸国や中東では、診断技術や研究に多額の投資が行われており、市場の潜在性が期待されています。アジア太平洋地域は、ヘルスケアの新興インフルエンサーが存在する地域であり、抗体フラグメントに対する需要が拡大しています。この分野における研究開発投資の増加は、この地域の市場成長が有望であることを示しています。同地域の顧客行動は、治療用途への傾倒を明らかにしており、多くのメーカーがこれを利用しようとしているため、同地域の市場成長はさらに高まっています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗体フラグメント市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗体フラグメント市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.抗体フラグメント市場の市場規模および予測は？

2.抗体フラグメント市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.抗体フラグメント市場の技術動向と規制枠組みは？

4.抗体フラグメント市場における主要ベンダーの市場シェアは？

5.抗体フラグメント市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 医療診断における抗体フラグメントの使用増加
    • さまざまながんや感染症の発生率の上昇
    • 創薬活動の増加
  • 抑制要因
    • 抗体フラグメントの承認に関する厳格な規制ガイドライン
  • 機会
    • 抗体フラグメントの臨床開発の進歩
    • 高度な組み換えDNA技術のイントロダクション
  • 課題
    • 抗がん免疫療法における不十分な有効性と副作用
• 市場セグメンテーション分析
  • タイプ：結合の安定性と柔軟性により、アプリケーションの観点から単一ドメイン抗体フラグメント（sdAbs）の使用が急増している
  • 抗体の種類：標的治療における高い特異性によりモノクローナル抗体の利用が拡大
  • 応用：がん治療における抗体フラグメントの応用の進化
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 抗体フラグメント市場：タイプ別

• F（ab）フラグメント
• F（ab'）2フラグメント
• 単一ドメイン抗体フラグメント（sdAbs）
• 単鎖可変フラグメント（scFv）

第7章 抗体フラグメント市場：抗体タイプ別

• モノクローナル
• ポリクローナル

第8章 抗体フラグメント市場：用途別

• がん
• 免疫不全

第9章 南北アメリカの抗体フラグメント市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の抗体フラグメント市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの抗体フラグメント市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • ルピン社とアンマンファーマ社がラニビズマブの独占販売で提携
  • バーミンガム血小板グループが画期的な「ナノボディ」技術を発表
  • カリフォルニアの新興バイオテクノロジー企業アトビアは、薬物が標的に結合する方法を再考する計画を掲げて設立されました。
• 戦略分析と提言

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. ANTIBODY FRAGMENTS MARKET RESEARCH PROCESS
• FIGURE 2. ANTIBODY FRAGMENTS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ANTIBODY FRAGMENTS MARKET DYNAMICS
• FIGURE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIBODY FRAGMENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB')2 FRAGMENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB')2 FRAGMENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 30. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 31. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 32. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 33. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 34. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 37. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 38. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 39. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 40. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 41. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 42. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 43. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 44. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 45. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 46. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 47. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 48. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 49. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 50. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 51. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 52. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 53. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 54. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 55. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 56. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 57. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 58. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 59. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 60. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 61. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 62. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 63. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 64. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 65. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 66. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 70. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 72. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 74. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 77. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 78. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 79. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 80. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 81. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 82. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 83. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 84. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 85. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 86. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 87. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 88. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 89. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 90. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 91. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 92. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 93. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 94. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 95. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 96. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 97. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 98. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 99. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 100. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 101. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 102. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 103. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 104. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 105. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 106. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 107. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 108. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 109. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 110. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 111. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 112. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 113. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 114. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 115. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 116. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 117. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 118. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 119. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 120. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 121. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 122. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 123. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 124. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 126. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 128. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 130. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 131. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 132. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 133. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 134. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 135. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 136. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 137. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 138. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 139. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 140. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 141. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 142. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 143. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 144. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 145. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 146. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 147. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 148. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 157. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 158. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 159. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 160. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 161. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 162. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 163. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 164. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 165. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 166. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 167. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 168. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 169. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 170. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 171. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 172. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 173. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 174. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 175. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 176. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 177. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 178. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 179. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 180. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 181. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 182. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 183. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 184. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 185. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 186. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 187. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 188. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 189. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 190. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 191. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 192. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 193. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 194. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 195. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 196. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 197. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 198. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 199. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 200. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 201. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 202. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 203. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 204. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 205. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 206. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 207. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 208. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 209. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 210. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 211. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 212. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 213. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 214. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 215. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 216. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 217. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 218. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 219. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 220. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 221. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 222. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 223. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 224. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 225. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 226. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 227. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 228. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 229. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 230. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 231. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 232. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 233. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 234. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 236. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 238. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 240. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 242. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 244. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 247. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 248. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 249. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 250. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 251. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 252. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 253. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 254. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 255. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 256. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 257. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 258. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 259. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 260. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 261. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 262. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 263. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 264. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 265. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 266. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 267. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 268. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 269. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 270. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 278. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 280. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 282. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 283. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 284. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023

[189 Pages Report] The Antibody Fragments Market size was estimated at USD 7.72 billion in 2023 and expected to reach USD 8.07 billion in 2024, at a CAGR 4.36% to reach USD 10.42 billion by 2030.

Antibody fragments refer to parts of antibodies capable of binding to specific types of antigens, the foreign substances in the body that induce an immune response. Antibody fragments are usually derivatives from whole antibodies and are developed through enzyme digestion or genetic engineering techniques. The primary driver of this market development is the increasing adoption of targeted therapies for treating chronic conditions, such as autoimmune diseases. Advancements in genetic and biochemical technologies have also paved the way for enhanced production and engineering of these fragments, boosting growth. A constant increase in R&D funding and robust healthcare infrastructure, especially in developed countries, contributed to overall market growth. However, the high costs of producing and purifying antibody fragments can restrict market growth. Regulatory challenges and lack of awareness in emerging markets also pose potential growth restrictions. New avenues for potential opportunities include the development of innovative drugs using antibody fragments and their usage in untapped disease areas. Additionally, the expansion and consolidation of pharmaceutical and biotechnological efforts in emerging markets also present significant opportunities for growth in the antibody fragments market.

Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding

F(ab) Fragments are small antibody fragments that contain one antigen-binding (Fab) site. It does not present the conserved Fc region; therefore, it cannot destroy cells through antibody-dependent cellular cytotoxicity. Applications include imaging and diagnostics. F(ab')2 Fragments, compared to F(ab), contain two antigen-combining sites, enabling the antibody to bind more vigorously to its targets. It is appreciated for allowing a more concentrated tracking accuracy in in-vivo imaging. Single domain antibody fragments (sdAbs) are known for their high solubility, thermal stability, and ability to bind to enzyme active sites, making their uses variegated in therapeutics and undergoing research. Single-chain variable fragments (scFvs) have binding specificity similar to monoclonal antibodies. They are preferred for targeted drug delivery and immunotherapy as efficient tools for the design of antibody derivatives.

Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics

Monoclonal antibodies(MAbs) are identical antibodies made by a single B-cell clone. They are specific for a single antigenic determinant, resulting in high specificity, consistently high quality, and unlimited supply. On a needs-based perspective, monoclonal antibodies are preferred in situations necessitating a high degree of specificity, such as in assays for detection and quantification of specific proteins, therapeutic areas such as oncology, autoimmune disorders, and in cell and tissue staining where it's critical to detect only the antigen of interest. Polyclonal antibodies (PAbs) are a mix of antibodies produced by different B cell clones in the body, each recognizing a different epitope of an antigen. This results in a broad-spectrum response that can be beneficial under certain conditions. Polyclonal antibodies are preferred in research requiring robust signals in detection systems such as Western blot, ELISA, or immunohistochemistry. Their capacity to bind multiple epitopes under varying conditions makes the PAbs more forgiving to slight changes in antigen conformation. It can offer a higher overall binding affinity than monoclonal antibodies.

Application: Evolving application of antibody fragments in cancer therapy

Antibody fragments in cancer therapy have been regarded as a breakthrough in oncology research. Their small size makes them penetrate and bind to cancer cells more efficiently than whole antibodies. Moreover, they minimize the risk of collateral damage to healthy cells, offering a more targeted treatment approach. Antibody fragments have been crucial in the treatment of immunodeficiencies. They help replace missing or inadequate antibody responses, improving the patient's ability to fight off infections. They offer more personalized treatment owing to their ability to be engineered to target specific disease biomarkers. Cancer treatment mainly focuses on the targeted elimination of cancer cells, whereas, in immunodeficiencies, antibody fragments are employed to boost the body's immune response.

Regional Insights

The Americas has a significant landscape in the antibody fragments market owing to ongoing research initiatives that pave the way for the market's growth. The purchasing behavior in these countries is predominantly driven by the advent of personalized medicine, with a notable focus on disease-specific applications. With the rising private and government entities' investments in next-generation healthcare technologies, further growth is anticipated. Europe, the Middle East, and Africa (EMEA) exhibit a burgeoning market for antibody fragments, driven by a rise in health consciousness and governmental initiatives for public health. The increase in lifestyle diseases in these regions has necessitated innovative therapeutics in the healthcare sector. EU countries and the Middle East are experiencing heavy investments in diagnostic technologies and research, thus promising market potential. The Asia Pacific region, home to emerging healthcare influencers, is witnessing a growing demand for antibody fragments. Increased investments in research & development in the field indicate a promising market growth in this region. The customer behavior in this region reveals an inclination towards therapeutic applications, which many manufacturers are looking to capitalize on, further increasing the market growth in the area.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Fragments Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Fragments Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Fragments Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Aenova Group GmbH, Almac Group, Amgen Inc., Antikor Biopharma, Astellas Pharma Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, Confo Therapeutics, Dyne Therapeutics, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilde Healthcare, Johnson & Johnson Services, Inc., MoonLake Immunotherapeutics AG, Novartis AG, Numab AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Fragments Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • F(ab) Fragments
  • F(ab')2 Fragments
  • Single Domain Antibody Fragments (sdAbs)
  • Single-chain Variable Fragments (scFvs)

• Antibody Type
  • Monoclonal
  • Polyclonal

• Application
  • Cancer
  • Immunodeficiencies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Fragments Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Fragments Market?

3. What are the technology trends and regulatory frameworks in the Antibody Fragments Market?

4. What is the market share of the leading vendors in the Antibody Fragments Market?

5. Which modes and strategic moves are suitable for entering the Antibody Fragments Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing use of antibody fragments in medical diagnostics
    • 5.1.1.2. Rising incidences of various cancers and infectious diseases
    • 5.1.1.3. Increasing number of drug discovery activities
  • 5.1.2. Restraints
    • 5.1.2.1. Strict regulatory guidelines for the approval of antibody fragments
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in the clinical development of antibody fragments
    • 5.1.3.2. Introduction of advanced recombinant DNA technology
  • 5.1.4. Challenges
    • 5.1.4.1. Insufficient efficacy and adverse effects in anticancer immunotherapy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding
  • 5.2.2. Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics
  • 5.2.3. Application: Evolving application of antibody fragments in cancer therapy
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Antibody Fragments Market, by Type

• 6.1. Introduction
• 6.2. F(ab) Fragments
• 6.3. F(ab')2 Fragments
• 6.4. Single Domain Antibody Fragments (sdAbs)
• 6.5. Single-chain Variable Fragments (scFvs)

7. Antibody Fragments Market, by Antibody Type

• 7.1. Introduction
• 7.2. Monoclonal
• 7.3. Polyclonal

8. Antibody Fragments Market, by Application

• 8.1. Introduction
• 8.2. Cancer
• 8.3. Immunodeficiencies

9. Americas Antibody Fragments Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Antibody Fragments Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Fragments Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Lupin, Amman Pharma Collaborates for Exclusive Marketing of Ranibizumab
  • 12.3.2. Birmingham Platelet Group Delivers Breakthrough 'nanobody' Technology
  • 12.3.3. Attovia, a new California biotech, Launches with Plans to Rethink how Drugs Bind their Targets
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio